Vaginal cancer
Primary vaginal cancer is a rare gynecologic malignancy, usually squamous cell carcinoma linked to HPV, that must be distinguished from the far more common metastatic or direct extension of cervical, endometrial, or vulvar cancer into the vagina. Diagnosis rests on biopsy of a visualized lesion with clinical FIGO staging, and treatment is predominantly radiation with concurrent platinum-based chemosensitization.
- Topic reviewThe full article, organized the way the exam asks it.
- ABIM-format MCQsVignettes with an explanation for every wrong answer.
- Key factsThe numbers and thresholds worth memorizing, up front.
- AI tutorMedBrain answers the question you're stuck on.
What this article covers
- Overview
Definition: a primary malignancy arising in the vaginal wall, diagnosed only after a cervical or vulvar primary has been excluded, since a tumor involving the cervix is classified as cervical cancer.
- Epidemiology
Age distribution by histology: squamous cell carcinoma occurs predominantly in older women, similar to squamous cervical cancer, while clear cell adenocarcinoma classically affects young women with in-utero DES exposure.
- Risk factors
Human papillomavirus infection: the dominant driver of vaginal squamous cell carcinoma and its precursor VAIN, mirroring the HPV-driven pathway of cervical dysplasia and cancer and HPV-related vulvar disease.
- Pathophysiology
HPV-driven squamous carcinogenesis: persistent infection with high-risk HPV subtypes drives dysplastic transformation of vaginal squamous epithelium, progressing through VAIN to invasive squamous…
- Clinical features
Abnormal vaginal bleeding: the most common presenting symptom, classically postcoital or postmenopausal bleeding, reflecting a friable mucosal lesion.
- Differential diagnosis
Cervical cancer with vaginal extension: the tumor involves the cervix as well as the vagina; by convention this is classified as cervical cancer, so cervical involvement must be excluded before…
- Diagnosis
Diagnosis is established by direct visualization and biopsy, with cervical and vulvar primaries specifically excluded: speculum exam or colposcopy identifies the lesion, biopsy confirms malignant…
- Management
Confirm histology and clinical FIGO stage before treatment planning, since management is individualized by stage, size, and location within the vagina rather than a single fixed protocol.
- Complications
Fistula formation: tumor necrosis or radiation injury can produce a vesicovaginal or rectovaginal fistula, causing continuous urinary or fecal leakage per vagina (vesicovaginal fistula, rectovaginal fistula).
- Prognosis
Stage at diagnosis is the dominant prognostic factor, with localized, early-stage disease carrying substantially better outcomes than disease extended to the pelvic sidewall or distant sites.
- Prevention
HPV vaccination: 9-valent HPV vaccine, routine series beginning at age 11 to 12 years (may start at age 9), catch-up through age 26 years; 2 doses at months 0 and 6 to 12 if started before the 15th…
Read the whole article
Subscribing to Internal Medicine opens every article, the full question bank and MedBrain, on the web, iPhone and Android.
Related articles
- Vulvar cancer
Vulvar cancer is usually squamous cell carcinoma of the vulvar skin, arising either from high-risk HPV infection (younger, premenopausal patients) or from long-standing lichen sclerosus (older, postmenopausal patients), and is confirmed by punch biopsy of any persistent vulvar lesion or unexplained pruritus; treatment is surgical, with radical vulvectomy and inguinal lymphadenectomy for invasive disease.
- Endometrial cancer
Endometrial cancer is the most common gynecologic malignancy, most often a type I endometrioid adenocarcinoma driven by unopposed estrogen and heralded by postmenopausal bleeding. Any postmenopausal bleeding or thickened endometrial stripe prompts endometrial biopsy, and early-stage disease is treated with total hysterectomy and bilateral salpingo-oophorectomy, giving a favorable overall prognosis.
- Human papillomavirus (HPV) infection
Human papillomavirus is a nonenveloped DNA virus with low-risk types (6, 11) that cause warts and high-risk types (16, 18, and others) that drive cervical, anal, vulvar, penile, and oropharyngeal cancer, prevented by 9-valent vaccination and managed by type-specific screening rather than treatment of the virus itself.
- Evaluation of vaginal discharge
Abnormal vaginal discharge is triaged at the bedside with vaginal pH, the amine whiff test, and saline/KOH microscopy, and treated with metronidazole for bacterial vaginosis or trichomoniasis, fluconazole or clotrimazole for candidiasis, and ceftriaxone plus doxycycline for cervicitis.
- Vaginal foreign bodies
A retained object in the vagina, most often a forgotten tampon in a reproductive-age patient or a small toy or paper wad in a prepubertal child, presents with malodorous purulent discharge and can seed staphylococcal toxic shock syndrome; management is removal plus, if the TSS triad is present, vancomycin and clindamycin.